Glial cell line-derived neurotrophic factor (GDNF) has been shown to increase the survival and functioning of dopamine neurons in a variety of animal models and some recent human trials. However, delivery of any protein to the brain remains a challenge due to the blood/brain barrier. Here we show that human neural progenitor cells (hNPC) can be genetically modified to release glycosylated GDNF in vitro under an inducible promoter system. hNPC-GDNF were transplanted into the striatum of rats 10 days following a partial lesion of the dopamine system. At 2 weeks following transplantation, the cells had migrated within the striatum and were releasing physiologically relevant levels of GDNF. This was sufficient to increase host dopamine neuron survival and fiber outgrowth. At 5 weeks following grafting there was a strong trend towards functional improvement in transplanted animals and at 8 weeks the cells had migrated to fill most of the striatum and continued to release GDNF with transport to the substantia nigra. These cells could also survive and release GDNF 3 months following transplantation into the aged monkey brain. No tumors were found in any animal. hNPC can be genetically modified, and thereby represent a safe and powerful option for delivering growth factors to specific targets within the central nervous system for diseases such as Parkinson's.
Introduction
Glial cell line-derived neurotrophic factor (GDNF) was first isolated by virtue of its neuroprotective and trophic effects on dopamine neurons that are lost in Parkinson's disease (PD). 1 Although GDNF does not penetrate the brain from the blood, studies in Parkinsonian primates showed that direct infusion into the ventricles led to a reversal of symptoms. 2 Furthermore, a series of experiments in both monkeys and rats have shown that GDNF can prevent dopamine neuron cell loss and induce fiber sprouting in a wide range of different models of PD. 3 This led to a clinical trial where GDNF was administered via bolus injections directly into the ventricles of Parkinsonian patients. The outcome of this trial was negative, with some significant side effects reported. 4, 5 This may have been due to poor penetrance of GDNF from the ventricles into the deep lateral regions of the posterior putamen, a region preferentially affected in PD. In order to overcome this problem, GDNF has now been continually infused using pumps and catheters directly into the caudal putamen of patients with PD over a period of 3 years. The results of this open-label study showed that GDNF was safe and provided significant decreases in Parkinsonian symptoms, significant increases in dopamine storage within the brain and increased dopamine neuron sprouting based on post mortem data. [6] [7] [8] A second open-label study has also shown significant improvements in patients receiving similar doses of GDNF to only one side of the brain. 9 However, delivery of proteins via a catheter and pump is complex, the GDNF concentrations have to be very high, the pumps need regular refilling and delivery is to only a point source within the putamen. Furthermore, a recent double-blind trial delivering GDNF to a larger number of patients failed to show significant effects, although this study used a different delivery system and dose of GDNF to the open-label studies described above (Lang et al., personal communication). Clearly, alternative methods of drug delivery to the brain need to be developed.
Direct gene therapy using live virus has emerged as one alternative method of growth factor delivery, and has been shown to work well in both rodent and primate models of PD. [10] [11] [12] Unfortunately, there are risks that transport of live virus to ectopic regions of the central nervous system will produce side effects. 13 Furthermore, viral infection of the diseased host nervous system may lead to extra stress within already sick neurons and glia. Modification of cells in the culture dish before subsequent transplantation is termed ex vivo gene therapy and increases safety since no live virus is injected into the subject and host neurons do not need to be infected. Autologous fibroblasts are an obvious choice for ex vivo gene therapy. They can be modified in the dish to release growth factors and survive transplantation for extended periods in the brain (for a review, see Gage 14 ) . Recently, this technique has been used to deliver nerve growth factor to the basal forebrain of 10 patients with Alzheimer's disease with some modest clinical effects. 15, 16 While the use of autologous cells has some benefit, fibroblasts do not migrate following transplantation and so drug delivery is limited to only the immediate site of the transplant. Fortunately, autologous cells are not essential as allografts appear to be accepted in the human brain following only brief suppression based on fetal transplant studies in PD. 17 Recently, efficient methods have been developed for the extended growth and differentiation of well-characterized human neural progenitor cells (hNPC). These cells can be isolated from post-mortem fetal brain tissue and expanded for significant periods of time in culture. 18, 19 hNPC react very differently from fibroblasts or primary fetal tissue following transplantation. Rather than forming a transplant core of non-migrating cells, a single deposit can fill almost the entire striatum. 20, 21 Furthermore, a number of reports have shown that hNPC can differentiate into both astrocytes and neurons following transplantation into the nervous system. 18, 20, [22] [23] [24] [25] We have previously shown that non-modified hNPC can lead to functional restoration in a model of Huntington's disease, potentially through neuroprotective effects on dying striatal neurons. 21 However, naïve hNPC alone do not have any significant functional effects in models of PD. 26 Rodent neural progenitor cells that have been genetically modified to produce GDNF are physiologically active on dopamine neurons, both in vitro and following transplantation. 27 In addition, a mouse immortal cell line that produces GDNF, survives transplantation in rodent models of PD and prevents degeneration of dopamine neurons when transplanted before the lesion has been generated. 28, 29 While these studies highlight the potential of GDNF-secreting cells, it will be crucial to demonstrate the efficiency of cells after rather than before the lesion to be relevant to PD. Furthermore, normal rat cells or immortalized mouse cells are not appropriate for human clinical trials which will require human cells.
GDNF has potent effects not only for PD but also for other neurological disorders, such as for amyotrophic lateral sclerosis (ALS) 30, 31 and for the aging process. 32 We have recently shown that hNPC engineered to produce GDNF and transplanted into the spinal cord can survive and increase motor neuron enzyme activity in a rodent model of ALS. 33 Here we use hNPC modified to release GDNF as a unique delivery option for this trophic factor to the parkinsonian rat and aged monkey brain.
Results
hNPC can be modified to release GDNF under a regulated promoter system
The inducible lentiviral construct used in this study is based on the already published non-inducible system described in detail previously 34 and is shown schematically in Figure 1 . The mouse phosphoglycerate kinase 1 (PGK) promoter (strong constitutive promoter) drives the tetracycline transactivator (tTA1) in the lenti-tTA Figure 1 The Tet-off lentiviral construct provides regulated GFP and GDNF production in hNPC. Cells were coinfected with lentitTA1 and either Approximately 40% of cells were shown to express GDNF following infection with the inducible GDNF construct (d). GDNF levels in the presence of doxycycline compared to those in the absence of doxycycline decrease following doxycycline treatment for 2 days and fall to over 90% shutdown in GDNF production following 10 days exposure (e). This regulation was dynamic as when doxycycline was removed for an 8-day washout, GDNF expression switched on again to levels similar to those seen before switch off (f). Scale bars are 125 mm in (b) and 40 mm in (d).
Human neural progenitors releasing GDNF S Behrstock et al construct. The post-translational cis-acting regulatory element of the woodchuck hepatitis virus (WHV) is included and has been shown to significantly enhance transgene expression. 34 In the absence of doxycycline, tTA1 will bind to the tetracycline operon (tetO) that is upstream of a minimal promoter driving the gene of interest. In this case, the gene is GDNF in the ind lenti-GDNF construct or enhanced green fluorescent protein (GFP) in the ind lenti-GFP construct. In the presence of doxycycline, the tTA is unable to activate the transgene.
The ind lenti-GFP construct ( Figure 1a ) was used to optimize lentiviral infection of hNPC and subsequent gene regulation. Small, intact spheres (o200 mm) were co-infected with lenti-tTA and ind lenti-GFP, resulting in a high percentage of GFP-expressing cells (Figure 1b) . In the presence of doxycycline for 48 h, the destabilized form of GFP was almost entirely shut off (Figure 1b) . Robust GFP expression returned when doxycycline was removed for 48 h, suggesting that tight and reversible regulation of this marker gene could be achieved ( Figure  1b ). Lentiviral infection of hNPC did not affect proliferation or differentiation, shown by continued neurosphere growth and expected numbers of astrocytes and neurons (data not shown).
Having optimized lentiviral infection and regulation of human neural cells using the visible GFP reporter, neurospheres were next co-infected with the lenti-tTA and either ind lenti-GFP or ind lenti-GDNF constructs ( Figure 1a ). Neurospheres infected with both lenti-tTA and ind lenti-GFP did not release GDNF at levels measurable with ELISA, Western blot or immunocytochemistry (data not shown). This confirms our earlier results using gene chip analysis for human neurospheres 19 and ELISA for rodent neurospheres. 27 Neurospheres co-infected with both lenti-tTA and the ind lenti-GDNF construct (hNPC-GDNF) produced large amounts of glycosylated GDNF revealed by Western blot analysis (Figure 1c , lane 3). This naturally glycosylated GDNF was similar to the glycosylated form produced by a non-human mammalian cell line (Figure 1c , lane 1) and was in contrast to the lighter-weight nonglycosylated human recombinant GDNF produced by bacteria ( Figure 1c , lane 2) and used for previous clinical trials. 6 Immunocytochemistry for GDNF showed that over 40% of the hNPC following infection expressed GDNF while other cells were completely negative following acute neurosphere dissociation and plating for 1 h (Figure 1d ). The protein was seen to accumulate within cells and had a punctate appearance consistent with normal production in golgi and release into the medium (Figure 1d ). Addition of doxycycline to the media significantly reduced GDNF levels overtime to approximately 10% of 'on' values without doxycycline by 10 days (Figure 1e ). The reason for this slow and incomplete shut off in GDNF protein levels when compared to GFP may be related to the long half-life of GDNF. hNPC-GDNF plated for 8 days were shown to release approximately 8-10 ng GDNF/mg of protein into the medium over a 24-h period (Figure 1f ). GDNF release could be switched off by doxycycline treatment and on again by removing doxycycline from the medium for 8 days (Figure 1f) , showing that the regulation was reversible. GDNF-transduced hNPC remained healthy, continued to expand and produced stable amounts of GDNF for at least 20 weeks in culture.
Thus, hNPC can be modified to secrete naturally glycosylated and regulated human GDNF for long periods in vitro.
GDNF release from hNPC is physiologically active in vitro
Having shown that hNPC-GDNF release high levels of the protein, we proceeded to establish the possible functional effects in vitro. Primary rat dopamine neurons were cultured in basal media, supernatant from hNPC or supernatant from hNPC-GDNF. The dopamine neurons were grown under minimal culture conditions to induce stress and subsequent low survival rates. The number of primary neurons staining for tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine production, significantly increased when media from wild-type human neurospheres was added 1 h after plating. This suggests a protective effect from secreted factors produced by the hNPC (Po0.001; Figure 2a and c) and supports our earlier observations that neural stem cells alone can increase the survival of primary dopamine neurons. 35 Supernatant from hNPC-GDNF had effects on overall dopamine neuron number comparable to that produced from wild-type hNPC ( Figure 2c ). In contrast, conditioned supernatant from hNPC-GDNF significantly increased both dopamine neuron neurite outgrowth and cell body area when compared with supernatant from wild-type hNPC (Po0.001; Figure 2b , d and e). Together, these data show that, while conditioned media (CM) Figure 2 Functional effects of GDNF released from hNPC in vitro. Following plating of primary rat dopamine neurons, overall survival was significantly enhanced with either CM from wildtype hNPC or hNPC-GDNF (a-c). However, when the fiber length (d) or cell body area (e) of dopamine neurons was assessed, significant increases were seen only in response to CM from hNPC-GDNF.
Human neural progenitors releasing GDNF S Behrstock et al from human neural cells is protective for dopamine neurons, only hNPC modified to release GDNF can achieve powerful trophic effects on dopamine fiber outgrowth and cell body area.
hNPC-GDNF induce dopamine fiber outgrowth 2 weeks following transplantation into the partially 6-hydroxydopamine (6OHDA)-lesioned rat brain
In order to establish whether the hNPC-GDNF could survive for short time periods following transplantation and modulate dopaminergic function, we grafted 120 000 cells into the striatum of rats with unilateral partial terminal lesions of the dopaminergic system pre-existing 1 week prior to transplantation. In this partial lesion, 6OHDA injected into the striatum selectively damages a proportion of dopaminergic fibers modeling the expected situation in the human striatum of a patient with mid-stage PD. 36 The results are described in Figure 3a . Animals had a reproducible partial lesion damage evidenced by loss of TH expression within the lesion core and penumbra and intact expression in distal/surrounding regions. GDNFexpressing hNPC survived transplantation into the core of the lesion and were detected using a human nucleispecific antibody (hNUC). GDNF staining revealed a good correlation between surviving hNPC-GDNF stained with hNUC marker and GDNF expression, although there was some diffusion of GDNF away from the graft core. There was no GDNF staining in animals receiving wild-type hNPC transplants or on the nonlesioned side of the brain, demonstrating the selective release of GDNF from engineered cells and the specificity of this technique.
In every animal, regions of GDNF-expressing hNPC correlated with areas of high TH fiber intensity at 2 weeks post-transplantation (Figure 3a) . Since the TH fibers in the area of 6OHDA administration are generally gone 1 week post-lesion (the time at which the hNPC were transplanted), we assume that this represents sprouting of surrounding fibers into this region, although it is also possible that this represents a protection effect. In contrast, animals receiving wildtype hNPC showed no TH fiber sprouting, suggesting that the effect was due to GDNF release from the hNPC and not simply the cells alone (Figure 3a) . Cell counts of the total number of dopamine neurons surviving in each group revealed significantly more TH-positive cells on the transplanted side following hNPC-GDNF transplantation (Figure 3b ; Po0.05). GDNF is known to be retrogradely transported from terminals in the striatum back to the mesencephalon. 37 Animals with hNPC-GDNF transplants in the striatum showed GDNF expression in dopamine neurons within the mesencephalon (Figure 3c-e) , demonstrating that GDNF released in the striatum was taken up by dopaminergic terminals Figure 3 hNPC-GDNF survive in the partially lesioned striatum and protect dopamine neurons. Animals killed at 2 weeks show GDNF release from hNPC-GDNF, but not wild-type hNPC, and show TH fiber sprouting around the graft site (a). GDNF released from hNPC-GDNF transplants in the striatum increase the percentage of dopamine neurons remaining in the mesencephalon of the transplanted side (GDNF) compared to the non-transplanted side (Cont) (Po0.05) (b). The GDNF released from the hNPC in the striatum is transported back to TH-expressing cell bodies in the substantia nigra (c-e). Scale bars are 500 mm in (a) and 100 mm in (c).
Human neural progenitors releasing GDNF S Behrstock et al and retrogradely transported to dopaminergic cell bodies. We next asked whether GDNF released from the hNPC could be regulated in vivo. Transplanted animals were treated for 14 days with doxycycline, but we saw little downregulation of GDNF immunoreactivity in the grafts (data not shown). This is probably due to the incomplete downregulation of GDNF expression in this system as shown in vitro (Figure 1e) . Thus, further modifications to the viral construct may be required to reduce GDNF in vivo expression levels below detection.
Long-term survival and expression of hNPC-GDNF in the rat and primate brain
To establish whether the GDNF-expressing hNPC could induce functional recovery in this partial lesion model of PD, a larger group of animals were transplanted with 240 000 cells over two sites and tested for amphetamine-induced rotation before and after transplantation (Figure 4a ). Control (nontransplanted) animals showed significant spontaneous recovery over time (Figure 4b ) in this partial terminal lesion model of PD. We attribute this to the daily cyclosporine treatment received by all animals, which is known to lead to sprouting and protection of dopamine neurons in this model. 38 Notably, the group with hNPC-GDNF transplants recovered faster over the first 6 weeks of testing (Figure 4b ) although this did not reach significance when compared over the whole 10-week time course using ANOVA. Even though all animals showed functional recovery, there were significantly more dopamine neurons in the hNPC-GDNF transplant group (Figure 4c ; Po0.05), suggesting a survival-promoting effect even at this late time stage.
Anatomical analysis using the human nuclei-specific antibody revealed that hNPC-GDNF survived up to 9 weeks following transplantation and migrated away from the transplant to fill a large area of the striatum (Figure 4d ). Individual host neurons could be seen in the striatum decorated with GDNF based on immunocytochemical staining (Figure 4e ). Further analysis of GDNF expression revealed a substantial release of GDNF covering the striatum in all transplanted animals ( Figure  4f ). In contrast to Figure 3a , there was no increase in TH fiber expression in these long-term animals in regions of high GDNF activity and dense cell transplants. This may be due to a downregulation of TH in response to GDNF over long but not short time periods, as shown in a previous rodent study. 39 The graft anatomy clearly demonstrated that hNPC-GDNF had good survival and robust GDNF expression for a long period in 6OHDA-lesioned rats. To establish what types of cells had been generated, we double labeled sections with an antibody to glial fibrillary acidic protein (GFAP; astrocyte marker), nestin (progenitor marker) or NeuN (neuronal marker) along with the human specific nuclear antigen (hNUC). Immunohistochemistry revealed that very few of the cells had matured into astrocytes at this time point (o5% GFAP positive; Figure 5a ) and that none of the transplanted cells appeared to differentiate into neurons. A rare example of an astrocyte-differentiated cell is shown in Figure 5b -d. Instead, the majority of the transplanted migrating cells continued to express nestin (490% nestin positive; Figure 5e ).
In a small study, three aged rhesus monkeys were transplanted with hNPC-GDNF into the putamen. One animal died due to natural aging and/or cyclosporine complications, one showed no transplant perhaps due to rejection, but the last animal had a robust transplant that expressed high levels of GDNF 3 months after grafting ( Figure 6 ). This shows that the cells used in this study are able to survive and release GDNF in the primate brain for extended periods of time. Figure 4 hNPC-GDNF express GDNF long term in the partially lesioned striatum and provide protection. Rats receiving hNPC-GDNF or no cells post-lesion were assessed for functional recovery by amphetamine rotations (a). Rats receiving hNPC-GDNF had a trend towards fewer rotations at 5 and 6 weeks post-transplantation compared to the control group. By 8 weeks, control rats showed similar recovery from the partial lesion (b). More TH-positive neurons are present in the hNPC-GDNF-transplanted rats compared to no transplant rats (c). Cells, identified with the human nuclear specific antibody hNUC, survive for at least 9 weeks following transplantation (d) and release GDNF, which is taken up by host neurons (e) and distributed to cover a large region of the striatum (f). Scale bars are 500 mm in (d), 100 mm in (e) and 30 mm in (e inset).
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Discussion
Since the discovery of nerve growth factor, 40 there has been an intense interest in the potential of growth factors for restoring the damaged central nervous system. GDNF has been a focus due to its potent effects on dopamine neurons, 1 although it has since been found to bind to receptors and exert trophic effects on a variety of neurons within the brain. 41 As PD attacks a range of neural transmitter systems in addition to dopamine, this pleotrophic aspect of GDNF may benefit multiple neurons, leading to enhanced effects in patients. However, delivery of GDNF has been a consistent challenge. A few studies have used immortal rodent cell lines to deliver GDNF before the lesion and shown protection. 28 Here we show for the first time that genetically modified hNPC can act as long-term 'mini pumps' to deliver GDNF to specific regions of the rodent and primate brain. Furthermore, we show that transplanted cells had physiological effects on dopamine neurons after the parkinsonian lesion had been administered, which is critical since there are currently no predictive factors for PD.
Engineered GDNF-secreting hNPC were remarkably stable over multiple passages and consistently released the same level of glycosylated GDNF into the medium. This allows banking and full characterization of the cells prior to transplantation to provide a level of safety required for human clinical trials. Clearly, regulation of GDNF release would be of interest for clinical trials. Inducible promoter systems driving TH expression packaged in adenoviral vectors have been shown to work with hNPC both in vitro and in vivo. 42 We constructed a vector to attempt regulation of GDNF release following transplantation. While regulation in vitro was very efficient for the marker protein GFP, we could not switch off GDNF production below approximately 10% of control values. Furthermore, in vivo we were not able to detect down-regulation of GDNF in response to doxycycline. This result is similar to other reports where inducible vectors have been used to control the release of GDNF following direct injection of viral vectors to the brain, but only met with limited Human neural progenitors releasing GDNF S Behrstock et al success. 43 There are a number of reasons why regulation cannot be achieved in vivo. Perhaps the most parsimonious of these is that GDNF may have a long-half life when compared to TH or destabilized GFP although there is limited evidence in the literature at present. Another possibility is that even if GDNF expression in the brain is reduced by 90% with doxycycline this low amount may still be detected with the sensitive immunocytochemical assay. We are currently exploring this issue further and developing new single vector systems to improve the regulated production of GDNF and achieve 100% shut-off both in vitro and in vivo.
The safety of progenitor cell transplants is always a key concern. Neural tissues derived from mouse embryonic stem cells can form teratomas in the brain. 44 In contrast, the human progenitor cells used in the current study are derived from fetal brain tissue, not human embryonic stem cells. Fetal-derived hNPC have been transplanted in hundreds of studies and never been found to form tumors to date. Our unique method of hNPC propagation permits constant cell/cell contact and eliminates exposure to serum or trypsin and stress from single-cell dissociation. 18 This technique may reduce the possibility of immortalization events seen in human embryonic stem cells associated with repetitive trypsin treatment and dissociation to single cells. 45 We have previously shown that hNPC grown as neurospheres without dissociation during passage do not express telomerase required for immortalization 46 and therefore have a finite lifespan in culture (Wright et al., in preparation). We have also shown that transplanted hNPC express Ki67 and divide in vivo for only a limited time. 46 In the current study, we confirm these observations as there was no sign of overgrowth or tumor formation. In addition, hNPC grown as neurospheres are never exposed to mouse feeder layers, reducing the possibility of contamination recently reported for human embryonic stem cells. 47 Human neural progenitors can be expanded to large numbers, genetically modified, tested for safety, banked, and may be more accepted after transplantation due to their human neural origin. Thus, these cells represent an ideal vehicle for delivering proteins to the human brain.
Transplants of hNPC-GDNF survived well in the brain for an extended time period, released GDNF at robust levels and increased the number of TH neurons and their fiber projections around the transplant site. Many of the transplanted cells (490%) maintained an immature phenotype, as evidenced by constant nestin expression. This may reflect the long time course of maturation required for human progenitor cells when compared to rodent progenitors, or the lack of appropriate speciesspecific differentiation signals in the rodent brain. Naïve hNPC had no effect on either survival or TH fiber sprouting, supporting our previous findings. 26 This is in contrast to a study that suggested that naïve immortalized mouse stem cells derived from the developing cerebellum (C17.2 cells) could restore dopamine neurons and function in a mouse model of PD. 29 However, this may be due to the fact that C17.2 cells were found to endogenously release GDNF, in contrast to the hNPC described in the current study. At five and six weeks following transplantation, animals with hNPC modified to express GDNF showed a trend towards functional effects when compared to control animals. By 10 weeks, this difference was no longer present due to spontaneous recovery in the control group. This may either be due to a lack of complete lesion in these animals, or some protective effects of the cyclosporin treatment. 38 In aged monkeys, hNPC-GDNF could survive and produce GDNF for up to 3 months, showing that this method of delivery is also applicable to primates.
hNPC can be modified in culture and survive transplantation into compromised environments, including the lesioned rodent striatum, the aged primate brain and, as recently shown by our laboratory, the spinal cord of ALS rats. 33 Cells continue to act as mini-pumps for several months, with release of the therapeutic molecule reaching physiological levels. Together, these results show that combining human progenitor cell therapy with ex vivo gene therapy is a powerful approach to the future treatment of PD and other neurological conditions.
Materials and methods
Cell growth
Human cortical neural progenitor cells were isolated from fetal cortex between 10 and 15 weeks of gestation according to protocols approved by the NIH and local ethics committee at the University of Wisconsin Madison and by the University of Washington Birth Defects Laboratory. Following dissociation in 0.1% trypsin, cells were seeded at 200 000 cells/ml in T75 flasks containing DMEM/Ham's F12 (Gibco-BRL) supplemented with penicillin/streptomycin (Gibo-BRL, 1%), N2 (Gibco-BRL, 1%), epidermal growth factor (Sigma, 20 ng/ml) with heparin (Sigma, 5 mg/ml) and fibroblast growth factor-2 (R&D, 20 ng/ml). Neurosphere colonies rapidly formed and were expanded by chopping using an automated tissue chopper as described in detail previously. 18 At 10 weeks the cells were switched to medium containing LIF (Chemicon, 10 ng/ml) and under these conditions the cultures could be grown for at least another 30 weeks in a relatively stable form based on gene expression patterns and differentiation potential. 19 
Lentiviral infection
The lentiviral particles were suspended in 1% fetal bovine serum albumin in phosphate-buffered saline. Lentivirus infection, except for the long-term transplant experiment, was 12 h in culture medium with 25 ng of ind lenti-GFP or ind lenti-GDNF and 75 ng of lenti-tTA per three spheres. For the long-term transplant experiment, we slightly modified the infection paradigm by dissociating spheres to single cells and infecting with only 5 ng of ind lenti-GDNF and 10 ng of lenti-tTA per 10 5 cells for 24 h before the virus was diluted out with fresh medium. New spheres were then formed through aggregation and allowed to expand for at least 5 weeks prior to transplantation.
GFP regulation
Following ind lenti-GFP infection, the GFP expression in a representative neurosphere was photographed, and a phase photograph was taken at the same time. This sphere was then cultured in media with doxycycline (Sigma, 0.1 mg/ml) for 48 h and again photographed under both fluorescence and phase. Doxycycline was removed from the media for 48 h. Following this Human neural progenitors releasing GDNF S Behrstock et al washout, a photograph was again taken under both fluorescence and phase.
Immunocytochemistry
Neurospheres infected with ind lenti-GDNF were dissociated using accutase (PAA Laboratories) and plated onto glass coverslips coated with poly-L-lysine (Sigma, 0.01%) and laminin (Sigma, 0.001%). Cells were plated at 30 000 per coverslip in differentiation media DMEM/ Ham's F12 with 2% B27 (Gibco-BRL) for 7 days. Following fixation with 4% paraformaldehyde and block in 10% normal donkey serum, cells were stained for GDNF (R&D, goat 1:500) with a cy3-conjugated secondary (Jackson Laboratories 1:1000) and hoechst.
GDNF quantification and regulation
Following ind lenti-GDNF infection, GDNF levels and regulation were assessed. Neurospheres were dissociated with accutase and equally divided into wells. Wells (n ¼ 3) were maintained in B27 differentiation media and wells (n ¼ 3) were maintained in B27 differentiation media with doxycycline (1 mg/ml). The plating media with or without doxycycline was collected every 2 days for 10 days and the samples were stored at À201C for later analysis. GDNF was measured in the supernatant from ind lenti-GDNF-infected neurospheres using a GDNF Elisa Kit (Promega), according to the manufacturer's instructions. For each collection day, we report GDNF levels in the plus doxycycline groups as a percentage of the GDNF levels in the minus doxycycline groups. In addition to confirming GDNF shut off overtime, we tested the reversible regulation of GDNF by measuring the supernatant from ind lenti-GDNF-infected cells plated in B27 differentiation media for 8 days without doxycycline, then with doxycycline for 8 days and finally following doxycycline washout for 8 days.
GDNF purification
Recombinant human GDNF (rhGDNF) was purified from ind lenti-GDNF-infected hNPC media using heparin affinity chromatography. A 10 ml Heparin Sepharose (Amersham Biosciences, Uppsala, Sweden) column was equilibrated with 50 mM Na 2 HPO 4 , pH 7.2. A volume of 2 liters of hNPC-GDNF CM was loaded onto the column at a flow rate of 20 ml/min. The column was washed with three column volumes of equilibration buffer and the GDNF was eluted with approximately 1 column volume of 50 mM Na 2 HPO 4 with 750 mM NaCl. The GDNF was collected in a 5 ml fraction and stored at À301C.
The rhGDNF from the heparin sepharose fraction was concentrated by TCA precipitation. TCA (Sigma, St Louis, MO, USA) was added at a ratio of 1.0 g TCA to 1.0 ml GDNF fraction. The precipitation proceeded at 41C for 30 min before centrifugation at 13 000 r.p.m. for 60 min. The precipitate was re-suspended in 1 Â LDS sample buffer (Invitrogen, Carlsbad, CA, USA) for SDS-PAGE and Western blot analysis.
Western blot
Western blot analysis was performed on partially purified rhGDNF from hNPC along with commercially available rhGDNF from the mouse mammalian cell line NSO (R&D Systems) and from Escherichia coli (Peprotech). Samples diluted in LDS sample buffer and reducing agent were heated to 701C for 5 min. SDS-PAGE was performed using NuPAGE s , 10% Bis-Tris gels (Invitrogen) and GDNF was transferred to a PVDF membrane using the XCell SureLockt and Blot Module. Western blot was performed using the WesternBreeze s Immunodetection Chromogenic kit (Invitrogen). GDNF was detected with a goat anti-GDNF primary antibody (R&D 1:500), followed by horseradish peroxidase (Dako  1:2000) .
GDNF functional effects in vitro
Primary ventral mesencephalon was dissected from E14 embryos of Sprague-Dawley rats and plated onto poly-Llysine-(0.01%) and laminin-(0.001%) coated coverslips. Cells were cultured for 7 days in either basal N2 (Gibco-BRL, 1%) media (n ¼ 3), supernatant from wild-type neurospheres (n ¼ 3) or supernatant from neurospheres infected with ind lenti-GDNF (n ¼ 3). Following fixation with 4% paraformaldehyde and rinses with phosphatebuffered saline, cell cultures were stained for TH (Chemicon, mouse 1:200) with FITC-conjugated secondaries (Jackson Laboratories, 1:1000) and hoechst. Cells were viewed under a fluorescent microscope and four fields were analyzed from each of the three coverslips per group. Fluorescent digital images were captured with a digital video camera using the Spot camera image analysis system. The number of TH-positive cells was quantified by counting cells immunoreactive for TH in 12 randomly selected fields. The neurite length and cell body size were quantified by using metamorph to determine the mm 2 and radius, respectively, for THpositive cells in 12 randomly selected fields.
Partial 6OHDA lesion
Adult male Lewis rats (300-350 g) were injected with a total of 21 mg of 6OHDA resuspended in 0.9% saline with 0.2 mg ascorbic acid. Injections of 7 mg/3.5 ml were made over three sites from bregma: AP +1.0, ML À3.0, DV À5.0; AP À0.1, ML À3.7, DV À5.0; AP À1.2, ML À4.5, DV À5.0.
Cell transplants
Cells were plated as neurospheres for 1 week in B27 differentiation media supplemented with cilliary neurotrophic factor (R&D, 5 ng/ml). To prepare cells for transplantation, the medium was removed, cells were rinsed and accutase was added for 15 min at 371C to detach plated spheres. Cells were collected, centrifuged at 1000 r.p.m. for 5 min, accutase was removed and cells were rinsed. Cells were incubated in DNAase for 10 min at 371C, centrifuged at 1000 r.p.m. for 5 min, DNAase was removed and cells were dissociated in Liebovitz/ 0.6% glucose (1:1) supplemented with 2% B27. Cells were counted, centrifuged at 1000 r.p.m. for 5 min, re-suspended at 66 500/ml and maintained on ice.
For the short-term (2-week) transplant experiments, hNPC (n ¼ 3) or hNPC-GDNF (n ¼ 3) were transplanted into one site at AP À0.3, ML À3.6, DV À5.2, 1 week postlesion. For the long-term (9-week) transplant experiments, hNPC-GDNF (n ¼ 9) were transplanted into two sites at AP +0.5, ML À3.3, DV À5.2 and AP À0.4, ML À3.7, DV À5.2, 10 days post-lesion. Control animals (n ¼ 4) received lesion, but no transplant. A 10 ml Hamilton syringe was lowered from dura, left in place for 1 min before injecting 3 ml cells over 3 min and For double labeling with human nuclei and nestin or GFAP antibodies, sections were processed as for nuclei staining, but primary antibodies were followed by mouse TRITC-and rabbit FITC-conjugated secondary antibodies (Jackson Labs, 1:1000). For nigral sections double labeled with TH and GDNF, sections were processed using tyramide signal amplification according to the manufacturer's instructions (Invitrogen) with mouse FITC-and goat TRITC-conjugated secondary antibodies (Jackson Labs, 1:1000).
GDNF functional effects in vivo
TH-positive neurons in the substantia nigra were viewed at Â 10 magnification under a light microscope. Images were captured with a digital video camera using the Spot image analysis system. At 2 and 8 weeks post-transplantation, TH-positive neurons were quantified ipsilateral and contralateral to the lesion in three anatomically equivalent sections through the substantia nigra. THpositive neuron survival was calculated as percent of TH-positive neurons remaining, and data are expressed as average percent TH neurons7s.e.m. (paired Student's t-test). Amphetamine-induced rotations (2.5 mg/kg) were assessed 1 week following a partial 6-OHDA lesion and animals with 4300 rotations/1.5 h were separated into balanced transplantation groups. Cells were transplanted 10 days following the lesion, and animals were retested weekly for amphetamine-induced rotations beginning 5 weeks post-transplantation.
Monkey studies
Three aged monkeys (22, 29 and 35 years of age) served as subjects. Coordinates for transplantation of GDNFexpressing hNPC were based upon MRI guidance. Under sterile conditions, monkeys received two injections of cells placed unilaterally into the caudate nucleus (10 and 5 ml) and three injections were placed into the putamen (10, 10 and 5 ml) on the same side. One animal died from natural causes 2 months following transplantation. The remaining 2 monkeys were killed 3 months following transplantation via perfusion with saline followed by fixation with a 4% Zamboni's fixitive. GDNF staining follows the protocol described in Kordower et al. (2000) .
